PHOENIX, AZ--(Marketwired - Feb 12, 2014) - Insys Therapeutics, Inc. (
Following the release of the financial results, Michael L. Babich, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 11:00 a.m. Eastern Standard Time.
Interested parties may participate in the conference call by dialing 888-427-9376 (U.S.) or 719-325-2308 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for two weeks by dialing 888-203-1112 (U.S.) or 719-457-0820 (International) and entering conference call ID number 8377866. A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.
Contact Information:
Contacts:
Darryl S. Baker
Chief Financial Officer
Insys Therapeutics, Inc.
602-910-2617
Lisa M. Wilson
President
In-Site Communications, Inc.
212-452-2793
E: lwilson@insitecony.com